The next wave of cellular immunotherapies in pancreatic cancer.
Full text not available from this repository.Item Type: | Review |
---|---|
Status: | Published |
Official URL: | https://doi.org/10.1016/j.omto.2022.01.010 |
Journal or Publication Title: | Molecular Therapy - Oncolytics |
Volume: | 24 |
Page Range: | pp. 561-576 |
Date: | 17 March 2022 |
Divisions: | Gene and Stem Cell Therapy |
Depositing User: | General Admin |
Identification Number: | 10.1016/j.omto.2022.01.010 |
ISSN: | 23727705 |
Date Deposited: | 26 Sep 2022 00:27 |
Abstract: | Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes. |
Creators: | Creators Email Yeo, Dannel UNSPECIFIED Giardina, Caroline UNSPECIFIED Saxena, Payal UNSPECIFIED Rasko, John E.J. UNSPECIFIED |
Last Modified: | 26 Sep 2022 00:27 |
URI: | https://eprints.centenary.org.au/id/eprint/1258 |
Actions (login required)
![]() |
View Item |